[1] Russo RA, Katsicas MM. Takayasu arteritis[J]. Front Pediatr, 2018, 6:265. [2] Tombetti E, Mason JC. Takayasu arteritis:advanced understanding is leading to new horizons[J]. Rheumatology (Oxford), 2019, 58:206-219. [3] Takamura C, Ohhigashi H, Ebana Y, Isobe M. New human leukocyte antigen risk allele in Japanese patients with Takayasu arteritis[J]. Circ J, 2012, 76:1697-1702. [4] Kim JE, Jeon JS. An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues[J]. Neurol Res, 2014, 36:407-416. [5] Phi JH, Wang KC, Lee JY, Kim SK. Moyamoya syndrome:a window of Moyamoya disease[J]. J Korean Neurosurg Soc, 2015, 57:408-414. [6] Kim JS. Moyamoya disease:epidemiology, clinical features, and diagnosis[J]. J Stroke, 2016, 18:2-11. [7] Lin R, Xie Z, Zhang J, Xu H, Su H, Tan X, Tian D, Su M. Clinical and immunopathological features of Moyamoya disease[J]. PLoS One, 2012, 7:E36386. [8] Sigdel TK, Shoemaker LD, Chen R, Li L, Butte AJ, Sarwal MM, Steinberg GK. Immune response profiling identifies autoantibodies specific to Moyamoya patients[J]. Orphanet J Rare Dis, 2013, 8:45. [9] Mahawish K, Teinert L, Cavanagh K, Brennan J. Limbic encephalitis[J]. BMJ Case Rep, 2014:ID2014204591. [10] Toudou-Daouda M, Filali-Adib A, Slassi A, Belahsen MF, Souirti Z. Limbic encephalitis:experience of a moroccan center[J]. Brain Behav, 2019, 9:E01177. [11] Howlett TA, Levy MJ, Robertson IJ. How reliably can autoimmune hypophysitis be diagnosed without pituitary biopsy[J]. Clin Endocrinol (Oxf), 2010, 73:18-21. [12] Kanoke A, Ogawa Y, Watanabe M, Kumabe T, Tominaga T. Autoimmune hypophysitis presenting with intracranial multi-organ involvement:three case reports and review of the literature[J]. BMC Res Notes, 2013, 6:560. [13] Takahashi Y. Autoimmune hypophysitis:new developments[J]. Handb Clin Neurol, 2014, 124:417-422. [14] Smith TJ. Advances in understanding autoimmune pituitary disease:standardized methods for autoantibody detection[J]. J Clin Endocrinol Metab, 2014, 99:1589-1592. [15] De Bellis A, Bizzarro A, Bellastella A. Pituitary antibodies and lymphocytic hypophysitis[J]. Best Pract Res Clin Endocrinol Metab, 2005, 19:67-84. [16] Khare S, Jagtap VS, Budyal SR, Kasaliwal R, Kakade HR, Bukan A, Sankhe S, Lila AR, Bandgar T, Menon PS, Shah NS. Primary (autoimmune) hypophysitis:a single centre experience[J]. Pituitary, 2015, 18:16-22. [17] Carbone A, Cesarman E, Spina M, Gloghini A, Schulz TF. HIV-associated lymphomas and gamma-herpesviruses[J]. Blood, 2009, 113:1213-1224. [18] Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. Long-term survival in AIDS-related primary central nervous system lymphoma[J]. Neuro Oncol, 2017, 19:99-108. [19] Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes:review and guidelines for recognition[J]. J Neurol Neurosurg Psychiatry, 2012, 83:638-645. [20] Seute T, Leffers P, ten Velde GP, Twijnstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma[J]. Cancer, 2004, 100:801-806. [21] Fischer A. Human primary immunodeficiency diseases[J]. Immunity, 2007, 27:835-845. [22] Lin TK, Yeh TH, Hsu PW, Chuang CC, Tu PH, Chen PY, Jung SM, Wei KC, Huang YC. Primary central nervous system lymphomas of the brain:a retrospective analysis in a single institution[J]. World Neurosurg, 2017, 103:550-556. |